Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Randomized Control Trial to Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis

NCT06147518 is registered in ClinicalTrials.gov with Institute of Liver and Biliary Sciences, India as lead sponsor.

NCT NCT06147518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06147518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Randomized Control Trial to Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis
Lead sponsor
Institute of Liver and Biliary Sciences, India
Phase
Not applicable
Overall status
Unknown status
Start date
December 20, 2023
Completion date
December 31, 2024
Enrollment
240 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

compensated cirrhosis, decompensated cirrhosis